Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.

Identifieur interne : 002959 ( PubMed/Corpus ); précédent : 002958; suivant : 002960

Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.

Auteurs : D E Zhang ; J P Rabek ; C C Hsieh ; C. Torres-Ramos ; J. Papaconstantinou

Source :

RBID : pubmed:1375227

English descriptors

Abstract

We have compared the activities of mouse alpha-fetoprotein (AFP) enhancers I, II, and III with their minimal enhancer fragments (Mers) I, II, and III and with the entire 7-kilobase pair enhancer domain by transient expression assay in primary fetal mouse liver cells. The level of expression directed by the AFP promoter [p(-1009)AFPcat] alone is stimulated at least 10-fold by the entire AFP enhancer domain (-1009 to -6983). Enhancer I can drive the level of chloramphenicol acetyltransferase activity equivalent to that of the entire enhancer domain, whereas the increase in activity by enhancers II and III is significantly lower (1.5-fold). MersI, II, and III all mediate a greater increase in activity than their corresponding enhancer regions. The increase with MerI is 16-fold. Using DNase I protection analyses we identified 3 protein-binding regions in MerI; site Ia binds liver and brain nuclear proteins; site Ib binds liver, kidney, and brain nuclear proteins as well as purified C/EBP; site Ic binds liver and kidney nuclear proteins. Site-specific mutation of Ia, Ib, or Ic showed a 10-25% reduction in chloramphenicol acetyltransferase expression; deletion of the C/EBP-binding site in Ib showed a 45% reduction in activity and mutation of all 3 sites (Ia, Ib, and Ic) resulted in a 75% reduction in activity. Our studies indicate no single trans-acting factor is absolutely essential for enhancer activity, and that the enhancer activity of MerI is mediated via a combinatorial and additive mechanism.

PubMed: 1375227

Links to Exploration step

pubmed:1375227

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.</title>
<author>
<name sortKey="Zhang, D E" sort="Zhang, D E" uniqKey="Zhang D" first="D E" last="Zhang">D E Zhang</name>
<affiliation>
<nlm:affiliation>Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rabek, J P" sort="Rabek, J P" uniqKey="Rabek J" first="J P" last="Rabek">J P Rabek</name>
</author>
<author>
<name sortKey="Hsieh, C C" sort="Hsieh, C C" uniqKey="Hsieh C" first="C C" last="Hsieh">C C Hsieh</name>
</author>
<author>
<name sortKey="Torres Ramos, C" sort="Torres Ramos, C" uniqKey="Torres Ramos C" first="C" last="Torres-Ramos">C. Torres-Ramos</name>
</author>
<author>
<name sortKey="Papaconstantinou, J" sort="Papaconstantinou, J" uniqKey="Papaconstantinou J" first="J" last="Papaconstantinou">J. Papaconstantinou</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1375227</idno>
<idno type="pmid">1375227</idno>
<idno type="wicri:Area/PubMed/Corpus">002959</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002959</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.</title>
<author>
<name sortKey="Zhang, D E" sort="Zhang, D E" uniqKey="Zhang D" first="D E" last="Zhang">D E Zhang</name>
<affiliation>
<nlm:affiliation>Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Rabek, J P" sort="Rabek, J P" uniqKey="Rabek J" first="J P" last="Rabek">J P Rabek</name>
</author>
<author>
<name sortKey="Hsieh, C C" sort="Hsieh, C C" uniqKey="Hsieh C" first="C C" last="Hsieh">C C Hsieh</name>
</author>
<author>
<name sortKey="Torres Ramos, C" sort="Torres Ramos, C" uniqKey="Torres Ramos C" first="C" last="Torres-Ramos">C. Torres-Ramos</name>
</author>
<author>
<name sortKey="Papaconstantinou, J" sort="Papaconstantinou, J" uniqKey="Papaconstantinou J" first="J" last="Papaconstantinou">J. Papaconstantinou</name>
</author>
</analytic>
<series>
<title level="j">The Journal of biological chemistry</title>
<idno type="ISSN">0021-9258</idno>
<imprint>
<date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Base Sequence</term>
<term>Brain (metabolism)</term>
<term>CCAAT-Enhancer-Binding Proteins</term>
<term>Cells, Cultured</term>
<term>Chloramphenicol O-Acetyltransferase (genetics)</term>
<term>Chloramphenicol O-Acetyltransferase (metabolism)</term>
<term>DNA</term>
<term>DNA Fingerprinting</term>
<term>DNA-Binding Proteins (metabolism)</term>
<term>Enhancer Elements, Genetic</term>
<term>Kidney (metabolism)</term>
<term>Liver (cytology)</term>
<term>Liver (metabolism)</term>
<term>Mice</term>
<term>Molecular Sequence Data</term>
<term>Mutagenesis, Site-Directed</term>
<term>Nuclear Proteins (metabolism)</term>
<term>Plasmids</term>
<term>RNA, Messenger (metabolism)</term>
<term>Transcription Factors (metabolism)</term>
<term>Transfection</term>
<term>alpha-Fetoproteins (genetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Chloramphenicol O-Acetyltransferase</term>
<term>alpha-Fetoproteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Chloramphenicol O-Acetyltransferase</term>
<term>DNA-Binding Proteins</term>
<term>Nuclear Proteins</term>
<term>RNA, Messenger</term>
<term>Transcription Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>CCAAT-Enhancer-Binding Proteins</term>
<term>DNA</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Brain</term>
<term>Kidney</term>
<term>Liver</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Base Sequence</term>
<term>Cells, Cultured</term>
<term>DNA Fingerprinting</term>
<term>Enhancer Elements, Genetic</term>
<term>Mice</term>
<term>Molecular Sequence Data</term>
<term>Mutagenesis, Site-Directed</term>
<term>Plasmids</term>
<term>Transfection</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We have compared the activities of mouse alpha-fetoprotein (AFP) enhancers I, II, and III with their minimal enhancer fragments (Mers) I, II, and III and with the entire 7-kilobase pair enhancer domain by transient expression assay in primary fetal mouse liver cells. The level of expression directed by the AFP promoter [p(-1009)AFPcat] alone is stimulated at least 10-fold by the entire AFP enhancer domain (-1009 to -6983). Enhancer I can drive the level of chloramphenicol acetyltransferase activity equivalent to that of the entire enhancer domain, whereas the increase in activity by enhancers II and III is significantly lower (1.5-fold). MersI, II, and III all mediate a greater increase in activity than their corresponding enhancer regions. The increase with MerI is 16-fold. Using DNase I protection analyses we identified 3 protein-binding regions in MerI; site Ia binds liver and brain nuclear proteins; site Ib binds liver, kidney, and brain nuclear proteins as well as purified C/EBP; site Ic binds liver and kidney nuclear proteins. Site-specific mutation of Ia, Ib, or Ic showed a 10-25% reduction in chloramphenicol acetyltransferase expression; deletion of the C/EBP-binding site in Ib showed a 45% reduction in activity and mutation of all 3 sites (Ia, Ib, and Ic) resulted in a 75% reduction in activity. Our studies indicate no single trans-acting factor is absolutely essential for enhancer activity, and that the enhancer activity of MerI is mediated via a combinatorial and additive mechanism.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">1375227</PMID>
<DateCompleted>
<Year>1992</Year>
<Month>06</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>267</Volume>
<Issue>15</Issue>
<PubDate>
<Year>1992</Year>
<Month>May</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.</ArticleTitle>
<Pagination>
<MedlinePgn>10676-82</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>We have compared the activities of mouse alpha-fetoprotein (AFP) enhancers I, II, and III with their minimal enhancer fragments (Mers) I, II, and III and with the entire 7-kilobase pair enhancer domain by transient expression assay in primary fetal mouse liver cells. The level of expression directed by the AFP promoter [p(-1009)AFPcat] alone is stimulated at least 10-fold by the entire AFP enhancer domain (-1009 to -6983). Enhancer I can drive the level of chloramphenicol acetyltransferase activity equivalent to that of the entire enhancer domain, whereas the increase in activity by enhancers II and III is significantly lower (1.5-fold). MersI, II, and III all mediate a greater increase in activity than their corresponding enhancer regions. The increase with MerI is 16-fold. Using DNase I protection analyses we identified 3 protein-binding regions in MerI; site Ia binds liver and brain nuclear proteins; site Ib binds liver, kidney, and brain nuclear proteins as well as purified C/EBP; site Ic binds liver and kidney nuclear proteins. Site-specific mutation of Ia, Ib, or Ic showed a 10-25% reduction in chloramphenicol acetyltransferase expression; deletion of the C/EBP-binding site in Ib showed a 45% reduction in activity and mutation of all 3 sites (Ia, Ib, and Ic) resulted in a 75% reduction in activity. Our studies indicate no single trans-acting factor is absolutely essential for enhancer activity, and that the enhancer activity of MerI is mediated via a combinatorial and additive mechanism.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo>
<Affiliation>Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rabek</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hsieh</LastName>
<ForeName>C C</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Torres-Ramos</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Papaconstantinou</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA31472</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022762">CCAAT-Enhancer-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000509">alpha-Fetoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9007-49-2</RegistryNumber>
<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.3.1.28</RegistryNumber>
<NameOfSubstance UI="D015500">Chloramphenicol O-Acetyltransferase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<GeneSymbolList>
<GeneSymbol>AFP</GeneSymbol>
</GeneSymbolList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D022762" MajorTopicYN="N">CCAAT-Enhancer-Binding Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015500" MajorTopicYN="N">Chloramphenicol O-Acetyltransferase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016172" MajorTopicYN="N">DNA Fingerprinting</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004742" MajorTopicYN="Y">Enhancer Elements, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000509" MajorTopicYN="N">alpha-Fetoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1992</Year>
<Month>5</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1992</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1992</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">1375227</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002959 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002959 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:1375227
   |texte=   Functional analysis of the mouse alpha-fetoprotein enhancers and their subfragments in primary mouse hepatocyte cultures.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:1375227" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021